新桥生物(NovaBridge Biosciences)最新发布的二期a阶段临床试验顶线数据显示,其核心候选药物Vis-101在治疗湿性年龄相关性黄斑变性(wet AMD)方面展现出卓越疗效。研究结果表明,该疗法能诱导快速起效、强劲且持久的治疗反应,为患者提供了新的希望。
新桥生物(NovaBridge Biosciences)最新发布的二期a阶段临床试验顶线数据显示,其核心候选药物Vis-101在治疗湿性年龄相关性黄斑变性(wet AMD)方面展现出卓越疗效。研究结果表明,该疗法能诱导快速起效、强劲且持久的治疗反应,为患者提供了新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.